Clare L. Scott
- Oncology top 0.2%
- Molecular Biology top 0.5%
- Reproductive Medicine top 0.1%
- Genetics top 0.5%
- Immunology top 1%
- Co-authors
- Michael FriedländerUrsula A. MatulonisAndreas StrasserJames CarmichaelJonathan A. LedermannCharlie GourleyTamar SafraPhilipp Harter
- Topics
- PARP inhibition in cancer therapy (49 papers)Ovarian cancer diagnosis and treatment (44 papers)BRCA gene mutations in cancer (30 papers)
- Partner nations
- AustraliaUnited KingdomUnited States
In The Last Decade
Clare L. Scott
171 papers receiving 13.0k citations
Hit Papers
Peers
Comparison fields: 5 of 175
- Oncology 6.6k
- Molecular Biology 6.5k
- Reproductive Medicine 2.6k
- Genetics 2.6k
- Immunology 1.8k
Countries citing papers authored by Clare L. Scott
This map shows the geographic impact of Clare L. Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clare L. Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clare L. Scott more than expected).
Fields of papers citing papers by Clare L. Scott
This network shows the impact of papers produced by Clare L. Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clare L. Scott. The network helps show where Clare L. Scott may publish in the future.
Co-authorship network of co-authors of Clare L. Scott
This figure shows the co-authorship network connecting the top 25 collaborators of Clare L. Scott. A scholar is included among the top collaborators of Clare L. Scott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clare L. Scott. Clare L. Scott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 4 | |
| 3 | 1 | |
| 4 | 3 | |
| 5 | 0 | |
| 6 | 13 | |
| 7 | 0 | |
| 8 | 9 | |
| 9 | 11 | |
| 10 | Chaperone-mediated protein degradation (CHAMP): A novel technology for tumor-targeted protein degradation. | 2 |
| 11 | 116 | |
| 12 | 6 | |
| 13 | SRA737, a novel Chk1 inhibitor, shows efficacy in CCNE1-amplified and MYCN-overexpressing high-grade serous ovarian cancer patient-derived xenograft models | 1 |
| 14 | Loss of RAD51C promoter hypermethylation confers PARP inhibitor resistance | 1 |
| 15 | Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer | 1 |
| 16 | 14 | |
| 17 | 45 | |
| 18 | 114 | |
| 19 | 38 | |
| 20 | 20 |
About Clare L. Scott
Clare L. Scott is a scholar working on Reproductive Medicine, Oncology and Cancer Research, having authored 177 papers that have together received 13.3k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (49 papers), Ovarian cancer diagnosis and treatment (44 papers) and BRCA gene mutations in cancer (30 papers). The work is most often cited by research in Reproductive Medicine (2.6k citations), Oncology (6.6k citations) and Cancer Research (1.6k citations). Clare L. Scott has collaborated with scholars based in Australia, United Kingdom and United States. Frequent co-authors include Michael Friedländer, Ursula A. Matulonis, Andreas Strasser, James Carmichael, Jonathan A. Ledermann, Charlie Gourley, Tamar Safra, Philipp Harter, Werner Meier and Ronnie Shapira‐Frommer. Their work appears in journals such as Science, New England Journal of Medicine and Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.